Biocon remains bullish on its market share prospects in the US, supported by over 70 per cent market access with payers and healthcare providers, said Matthew Erick, Chief Commercial Officer – Advanced Markets, during an investor call.

The company currently has over 100 million lives covered in the US, making it one of its most successful market access efforts to date, according to Erick. He also noted that pricing remains stable and that significant price compression is not expected through the rest of the year.

The US contributes a significant share of Biocon’s revenue. Around one-third of the company’s generics formulation business and 40–50 per cent of its biosimilars revenue currently come from the US market.

Biocon reported a consolidated revenue of ₹4,454 crore in Q4 FY25, up 15 per cent year-on-year. Net profit stood at ₹344 crore, marking a 153 per cent increase. The biosimilars segment recorded strong performance, with four products crossing ₹200 million in annual sales.

The generics business posted a 46 per cent y-o-y growth, primarily driven by new launches such as Lenalidomide and Dasatinib in the US, along with modest growth in its API division. Biologics continued its growth momentum, posting a 9 per cent year-on-year increase in Q4 FY25, driven by market share gains in the US and key tender wins in emerging markets.

fund raise

The board approved the company’s plans to raise up to ₹4,500 crore through the issue of securities via qualified institutional placement, rights issue, or other permissible routes. Additionally, the board is constituting a committee to evaluate various strategic options for restructuring, including a potential merger of Biocon Biologics and Biocon Ltd.

Published on May 11, 2025